Emergent BioSolutions (EBS) Receivables - Other (2017 - 2026)

Emergent BioSolutions' Receivables - Other history runs 10 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 40.78% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $18.3 million, a 40.78% decrease from a year earlier, with the FY2025 full-year figure at $18.2 million, down 7.14% from the prior year.
• Receivables - Other grew to $18.3 million in Q1 2026 per EBS's latest filing, from $18.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $82.5 million in Q2 2024 and bottomed at $18.2 million in Q4 2025.
• The 5-year median for Receivables - Other is $49.8 million (2023), against an average of $43.4 million.
• Across the five-year window, Receivables - Other surged 59.27% in 2024 and tumbled 72.24% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $57.2 million in 2022, then retreated by 10.14% to $51.4 million in 2023, then sank by 61.87% to $19.6 million in 2024, then decreased by 7.14% to $18.2 million in 2025, then gained by 0.55% to $18.3 million in 2026.
• Per Business Quant, the three latest EBS Receivables - Other figures stand at $18.3 million (Q1 2026), $18.2 million (Q4 2025), and $19.3 million (Q3 2025).